Progress on frontotemporal dementia

doi:10.3969/j.issn.1672-6731.2026.02.008

Abstract

Abstract: Frontotemporal dementia (FTD) is the second most common type of early-onset dementia after Alzheimer's disease (AD), severely impairing patients' quality of life and increasing the burden of family care. Currently, there is a lack of reliable biomarkers for its diagnosis, and reliance on clinical manifestations is prone to misdiagnosis and missed diagnosis. Additionally, there are no approved specific treatments for FTD, and the efficacy of existing therapeutic treatments remains limited. With the deepening research on the genetic mechanisms of FTD, the diagnostic and therapeutic treatments based on this have significant application prospects. This study systematically summarizes research findings in the fields of genetic mechanism, pathological classification, diagnosis and therapeutic treatments of FTD in recent years, aiming to provide a reference for comprehensive understanding of disease's pathogenesis and clinical characteristics, and to lay a foundation for exploring novel diagnostic and therapeutic strategies.

Key words: Frontotemporal dementia, Genes, Mutation, Biomarkers, Transcranial magnetic stimulation, Electric stimulation therapy, Review

摘要： 额颞叶痴呆是仅次于阿尔茨海默病的常见早发型痴呆，严重影响患者生活质量并带来沉重家庭和社会负担。目前疾病诊断主要依靠临床症状，缺乏可靠的生物学标志物，易漏诊或误诊，亦无针对性疾病修饰治疗，现有治疗方法效果有限。随着额颞叶痴呆遗传学机制研究的深入，以此为基础的诊断与治疗手段应用前景广阔，本文系统梳理额颞叶痴呆的遗传学机制、病理分型、诊断与治疗进展，旨在为深入理解疾病的本质特征提供理论依据，并为探索早期诊断与有效治疗的创新策略指引方向。

关键词: 额颞叶痴呆, 基因, 突变, 生物标记, 经颅磁刺激, 电刺激疗法, 综述

CLC Number:

R741

XU Yu-xuan, NAN Hai-tian, CHU Min, WU Li-yong. Progress on frontotemporal dementia[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2026, 26(2): 169-178.

徐语萱, 南海天, 褚敏, 武力勇. 额颞叶痴呆研究进展[J]. 中国现代神经疾病杂志, 2026, 26(2): 169-178.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2026.02.008

https://journal11.magtechjournal.com/cjcnn/EN/Y2026/V26/I2/169

References

[1] Chiari A, Vinceti G, Adani G, Tondelli M, Galli C, Fiondella L, Costa M, Molinari MA, Filippini T, Zamboni G, Vinceti M. Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy[J]. Alzheimers Dement, 2021, 17:81-88. Brayne C, Ray N, Logroscino G.
[2] Urso D, Giannoni-Luza S, Incidence and prevalence of frontotemporal dementia:a systematic review and Meta-analysis[J]. JAMA Neurol, 2025, 82:1144-1152.
[3] Kang SJ, Cha KR, Seo SW, Kim EA, Cheong HK, Kim EJ, Na DL, Jeong JH. Survival in frontotemporal lobar degeneration in a Korean population[J]. Alzheimer Dis Assoc Disord, 2010, 24:339-342.
[4] Coyle-Gilchrist IT, Dick KM, Patterson K, Vázquez Rodríquez P, Wehmann E, Wilcox A, Lansdall CJ, Dawson KE, Wiggins J, Mead S, Brayne C, Rowe JB. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes[J]. Neurology, 2016, 86:1736-1743.
[5] Piguet O, Clarke AJ, Foxe D, Tse NY, Teng H, Burrell JR, Cheung SC, Carrick J, Devenney E, Halliday GM, Kwok JB, Dobson-Stone C, Cordato NJ, Hwang YT, Hodges JR, Ahmed RM. Fourteen years later:reviewing the diagnostic criteria for behavioral-variant frontotemporal dementia[J]. Alzheimers Dement, 2025, 21:e 70604.
[6] Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN. The heritability and genetics of frontotemporal lobar degeneration[J]. Neurology, 2009, 73:1451-1456.
[7] Nan H, Kim YJ, Chu M, Li D, Li J, Jiang D, Wu Y, Ohtsuka T, Wu L. Genetic and clinical landscape of Chinese frontotemporal dementia:dominance of TBK1 and OPTN mutations[J]. Alzheimers Res Ther, 2024, 16:127. Y,
[8] Xu T, Weng L, Zhang C, Xiao X, Yang Q, Zhu Y, Zhou Liao X, Luo S, Wang J, Tang B, Jiao B, Shen L. Genetic spectrum features and diagnostic accuracy of four plasma biomarkers in 248 Chinese patients with frontotemporal dementia[J]. Alzheimers Dement, 2024, 20:7281-7295.
[9] Grossman M, Seeley WW, Boxer AL, Hillis AE, Knopman DS, Ljubenov PA, Miller B, Piguet O, Rademakers R, Whitwell JL, Zetterberg H, van Swieten JC. Frontotemporal lobar degeneration[J]. Nat Rev Dis Primers, 2023, 9:40. A,
[10] Majounie E, Renton AE, Mok K, Dopper EG, Waite Rollinson S, Chiò A, Restagno G, Nicolaou N, Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pamphlett R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O; Chromosome 9-ALS/FTD Consortium, French Research Network on FTLD/FTLD/ALS, ITALSGEN Consortium; Hernandez DG, Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris GL, Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ. Frequency of the C9 orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia:a cross-sectional study[J]. Lancet Neurol, 2012, 11:323-330.
[11] Woollacott IO, Mead S. The C9 ORF72 expansion mutation:gene structure, phenotypic and diagnostic issues[J]. Acta Neuropathol, 2014, 127:319-332.
[12] Tang M, Gu X, Wei J, Jiao B, Zhou L, Zhou Y, Weng L, Yan X, Tang B, Xu J, Shen L. Analyses MAPT, GRN, and C9 orf72 mutations in Chinese patients with frontotemporal dementia[J]. Neurobiol Aging, 2016, 46:235. e11-235. e15.
[13] Che XQ, Zhao QH, Huang Y, Li X, Ren RJ, Chen SD, Wang G, Guo QH. Genetic features of MAPT, GRN, C9 orf72 and CHCHD10 gene mutations in Chinese patients with frontotemporal dementia[J]. Curr Alzheimer Res, 2017, 14:1102-1108.
[14] Cheng HR, Lin RR, Li HL, Xue YY, Gao PR, Chen DF, Tao QQ, Wu ZY. Identification and functional characterization of novel variants of MAPT and GRN in Chinese patients with frontotemporal dementia[J]. Neurobiol Aging, 2023, 123:233-243.
[15] Jiao B, Liu H, Guo L, Xiao X, Liao X, Zhou Y, Weng L, Zhou L, Wang X, Jiang Y, Yang Q, Zhu Y, Zhou L, Zhang W, Wang J, Yan X, Li J, Tang B, Shen L. The role of genetics in neurodegenerative dementia:a large cohort study in South China[J]. NPJ Genom Med, 2021, 6:69.
[16] Jiao B, Tang B, Liu X, Yan X, Zhou L, Yang Y, Wang J, Xia K, Shen L. Identification of C9 orf72 repeat expansions in patients with amyotrophic lateral sclerosis and frontotemporal dementia in mainland China[J]. Neurobiol Aging, 2014, 35:936. e19-936. e22.
[17] Dong L, Wang J, Liu C, Li J, Mao C, Huang X, Chu S, Peng B, Cui L, Gao J. Genetic spectrum and clinical heterogeneity of Chinese frontotemporal dementia patients:data from PUMCH dementia cohort[J]. J Alzheimers Dis, 2022, 89:893-901.
[18] Liu L, Cui B, Chu M, Cui Y, Jing D, Li D, Xie K, Kong Y, Xia T, Wang C, Wu L. The frequency of genetic mutations associated with behavioral variant frontotemporal dementia in Chinese Han patients[J]. Front Aging Neurosci, 2021, 13:699836.
[19] Li Y, Yang Z, Zhang Y, Liu F, Xu J, Meng Y, Xing G, Ruan X, Sun J, Zhang N. Genetic screening of patients with sporadic Alzheimer's disease and frontotemporal lobar degeneration in the Chinese population[J]. J Alzheimers Dis, 2024, 99:577-593.
[20] Chen S, Zhou RL, Zhang W, Che CH, Feng SY, Huang HP, Liu CY, Zou ZY. Novel TARDBP missense mutation caused familial amyotrophic lateral sclerosis with frontotemporal dementia and parkinsonism[J]. Neurobiol Aging, 2021, 107:168-173.
[21] Jiao B, Xiao T, Hou L, Gu X, Zhou Y, Zhou L, Tang B, Xu J, Shen L. High prevalence of CHCHD10 mutation in patients with frontotemporal dementia from China[J]. Brain, 2016, 139(Pt 4):e21.
[22] Nuytemans K, Franzen S, Broce IJ, Caramelli P, Ellajosyula R, Finger E, Gupta V, Gupta V, Illán-Gala I, Loi SM, Morhardt D, Pijnenburg Y, Rascovsky K, Williams MM, Yokoyama JS, Acosta-Uribe J, Akinyemi R, Alladi S, Ayele BA, Ayhan Y, Bourdage R, Castro-Suarez S, de Souza LC, Dacks P, de Boer SCM, de Leon J, Dodge S, Grasso S, Ghoshal N, Kamath V, Kumfor F, Matias-Guiu JA, Narme P, Nielsen TR, Okhuevbie D, Piña-Escudero S, Ruiz-Garcia R, Ryan B, Scarioni Slachevsky A, Suarez-Gonzalez A, Tee BL, Tsoy E, Ulugut H, Onyike CU, Babulal GM; ISTAART Frontotemporal Dementia and Related Disorders PIA, ISTAART Diversity Disparities PIA. Gaps in biomedical research in frontotemporal dementia:a call for diversity and disparities focused research[J]. Alzheimers Dement, 2024, 20:9014-9036.
[23] Mirza SS, Pasternak M, Paterson AD, Rogaeva E, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Bouzigues A, Russell LL, Foster PH, Ferry-Bolder E, Bocchetta M, Cash DM, Zetterberg H, Sogorb-Esteve A, van Swieten J, Jiskoot LC, Seelaar H, Sanchez-Valle R, Laforce R Jr, Graff C, Galimberti D, Vandenberghe R, de Mendonça A, Tiraboschi P, Santana I, Gerhard A, Levin J, Sorbi S, Otto M, Pasquier F, Ducharme S, Butler C, Le Ber I, Finger E, Rowe JB, Synofzik M, Moreno F, Borroni B, Rohrer JD, Masellis M;GENetic Frontotemporal dementia Initiative modifying effects of TMEM106 B in genetic frontotemporal dementia:a longitudinal GENFI study[J]. Brain, 2025, 148:2746-2762.
[24] Swift SK, Huang G, Cochran JN, Minaya MA, Castruita PA, Miller KJ, Starr E, Galasso G, Marsh JA, Kao AW, Yokoyama JS, Karch CM. Integrative genomic and functional analyses reveal NINL as a modulator of Tau aggregation[EB/OL]. bioRxiv, 2025(2025-12-16)[2025-12-20]. https://www. biorxiv. org/content/10. 64898/2025. 12. 12. 694063 v1.
[25] Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration:predicting molecular pathology[J]. Nat Rev Neurol, 2012, 8:131-142.
[26] Creekmore BC, Watanabe R, Lee EB. Neurodegenerative disease tauopathies[J]. Annu Rev Pathol, 2024, 19:345-370.
[27] Morito T, Qi M, Kamano N, Sasaguri H, Bez S, Foiani M, Duff K, Benner S, Endo T, Hama H, Kurokawa H, Miyawaki A, Mizuma H, Sahara N, Shimojo M, Higuchi M, Saido TC, Watamura N. Human MAPT knockin mouse models of frontotemporal dementia for the neurodegenerative research community[J]. Cell Rep Methods, 2025, 5:101024.
[28] Buccellato FR, D'Anca M, Tartaglia GM, Del Fabbro M, Galimberti D. Frontotemporal dementia:from genetics to therapeutic approaches[J]. Expert Opin Investig Drugs, 2024, 33:561-573.
[29] Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A. Progranulin as a therapeutic target in neurodegenerative diseases[J]. Trends Pharmacol Sci, 2022, 43:641-652.
[30] Maheswari Jawahar V, Zeng Y, Armour EM, Yue M, Citrano K, Lovchykova A, Reeves MM, Rawlinson B, DeTure M, Dunmore JA, Song Y, Ball SK, Wszolek ZK, Graff-Radford NR, Boeve BF, Knopman DS, Day GS, Small SA, Dickson DW, Ward ME, Gendron TF, Zhang Y, Prudencio M, Gitler AD, Petrucelli L. TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia[J]. PLoS Biol, 2026, 24:e 3003573.
[31] Todd TW, Petrucelli L. Insights into the pathogenic mechanisms of Chromosome;
9 open reading frame 72(C9 orf72) repeat expansions[J]. J Neurochem, 2016, 138 Suppl 1:145-162.
[32] Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, Dickson DW. Neuropathological background of phenotypical variability in frontotemporal dementia[J]. Acta Neuropathol, 2011, 122:137-153.
[33] Carbayo Á, Borrego-Écija S, Turon-Sans J, Cortés-Vicente E, Molina-Porcel L, Gascón-Bayarri J, Rubio MÁ, Povedano M, Gámez J, Sotoca J, Juntas-Morales R, Almendrote M, Marquié M, Sánchez-Valle R, Illán-Gala I, Dols-Icardo O, Rubio-Guerra S, Bernal S, Caballero-Ávila M, Vesperinas A, Gelpi E, Rojas-García R. Clinicopathological correlates in the frontotemporal lobar degeneration-motor neuron disease spectrum[J]. Brain, 2024, 147:2357-2367.
[34] Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, Kril JJ, Halliday GM. Clinicopathological correlates in frontotemporal dementia[J]. Ann Neurol, 2004, 56:399-406.
[35] Simón-Sánchez J, Dopper EG, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, de Graaf JR, de Koning I, van Schoor NM, Deeg DJ, Smits M, Raaphorst J, van den Berg LH, Schelhaas HJ, De Die-Smulders CE, Majoor-Krakauer D, Rozemuller AJ, Willemsen R, Pijnenburg YA, Heutink P, van Swieten JC. The clinical and pathological phenotype of C9 ORF72 hexanucleotide repeat expansions[J]. Brain, 2012, 135(Pt 3):723-735.
[36] Meng Y, Li W, Zhang Y, Li Y, He Y, Zhang N. ANXA11 mutations in the FTD spectrum:a novel finding in a patient with semantic variant primary progressive aphasia[J]. Eur J Neurol, 2025, 32:e 70187.
[37] Scialò C, Zhong W, Jagannath S, Wilkins O, Caredio D, Hruska-Plochan M, Lurati F, Peter M, De Cecco E, Celauro L, Aguzzi A, Legname G, Fratta P, Polymenidou M. Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures[J]. Neuron, 2025, 113:1614-1628.
[38] Cui Y, Liu L, Chu M, Xie K, Chen Z, Nan H, Kong Y, Xia T, Wang Y, Wang Y, He Q, Wu L. Application of the mild behavioral impairment checklist in Chinese patients with the behavioral variant of frontotemporal dementia[J]. Neurol Sci, 2024, 45:557-564.
[39] Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia:the clinical overlap[J]. J Mol Neurosci, 2011, 45:343-349.
[40] Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17:a consensus conference[J]. Conference Participants, Ann Neurol, 1997, 41:706-715.
[41] Wu LY, Feng XY, Liu Y, Hao SS, Ding Y, Zhan SQ, Wang YP. Analysis of the clinical and sleep disorder characteristics of familial frontotemporal dementia complicated with Parkinson's syndrome[C] //Chinese Sleep Research Society. The;
7 th Chinese sleep medicine forum, Suzhou, 2017. Suzhou:Chinese Sleep Research Society, 2017:40[. 武力勇, 冯雪岩, 刘阳, 郝树森, 丁岩, 詹淑琴, 王玉平. 家族性额颞叶痴呆合并帕金森综合征临床和睡眠障碍特征分析[C] //中国睡眠研究会. 第七届中国睡眠医学论坛会议指南, 苏州, 2017. 苏州:中国睡眠研究会, 2017:40. ]
[42] Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, Hutton ML, Lin SC, Boeve BF, Cheshire WP, Pooley RA, Liss JM, Caviness JN, Strongosky AJ, Wszolek ZK. Clinical-pathologic study of biomarkers in FTDP-17(PPND family with N279 K tau mutation)[J]. Parkinsonism Relat Disord, 2007, 13:230-239.
[43] Panman JL, Jiskoot LC, Bouts MJRJ, Meeter LHH, van der Ende EL, Poos JM, Feis RA, Kievit AJA, van Minkelen R, Dopper EGP, Rombouts SARB, van Swieten JC, Papma JM. Gray and white matter changes in presymptomatic genetic frontotemporal dementia:a longitudinal MRI study[J]. Neurobiol Aging, 2019, 76:115-124.
[44] Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Rossor MN, Ourselin S, Rohrer JD; Genetic FTD Initiative, GENFI. Patterns of gray matter atrophy in genetic frontotemporal dementia:results from the GENFI study[J]. Neurobiol Aging, 2018, 62:191-196.
[45] Panman JL, Venkatraghavan V, van der Ende EL, Steketee RME, Jiskoot LC, Poos JM, Dopper EGP, Meeter LHH, Donker Kaat L, Rombouts SARB, Vernooij MW, Kievit AJA, Premi E, Cosseddu M, Bonomi E, Olives J, Rohrer JD, Sánchez-Valle R, Borroni B, Bron EE, Van Swieten JC, Papma JM, Klein S; GENFI Consortium Investigators. Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia[J]. J Neurol Neurosurg Psychiatry, 2021, 92:494-501.
[46] Cheran G, Silverman H, Manoochehri M, Goldman J, Lee S, Wu L, Cines S, Fallon E, Kelly BD, Olszewska DA, Heidebrink J, Shair S, Campbell S, Paulson H, Lynch T, Cosentino S, Huey ED. Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in MAPT mutation carriers[J]. J Neurol Neurosurg Psychiatry, 2018, 89:449-455.
[47] Wang J, Wang ZY, Chen SF, Wang RZ, Chen KL, Lu JY, Xin JW, Huang YY, Wang MY, Xie F, Cheng W, Yen TC, Wischik CM, Cui M, Zuo CT, Zhao QH, Wang YJ, Yu JT. Role of 18 F-florzolotau PET in diagnostic and therapeutic decision-making for cognitive impairment[J]. Alzheimers Dement, 2025, 21:e 70563.
[48] Chandrasekar SK, Arthanari J, Chandrasekar KK, Gaviria E, Shashank S, Jethi A, John J, Bopparaju S, Potulapati I, Mateen MA, Hussin OA. Advanced imaging techniques (PET, fMRI, DTI) in early detection of neurodegenerative diseases:a systematic review[J]. Health Sci Rep, 2025, 8:e 70855.
[49] Chu M, Yue A, Yan S, Yu B, He Q, Chen Y, Hou J, Nan H, Ye H, Nie B, Rosa-Neto P, Qu M, Lu J, Wu L. Glymphatic activity in behavioral variant frontotemporal dementia:link with vascular function and astrocytic activation[J]. Alzheimers Dement, 2025, 21:e 70561.
[50] Therriault J, Brum WS, Trudel L, Macedo AC, Bitencourt FV, Martins-Pfeifer CC, Nakouzi M, Pola I, Wong M, Kac PR, Real AP, Witherow C, Karikari TK, Moscoso A, Zimmer ER, Schöll M, Pascoal T, Benedet AL, Ashton NJ, Schindler SE, Zetterberg H, Blennow K, Rosa-Neto P. Blood phosphorylated tau for the diagnosis of Alzheimer's disease:a systematic review and meta-analysis[J]. Lancet Neurol, 2025, 24:740-752.
[51] Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H, VandeVrede L, Proctor NK, Lago AL, Baker S, Sivasankaran R, Kieloch A, Kinhikar A, Yu L, Valentin MA, Jeromin A, Zetterberg H, Hansson O, Mattsson-Carlgren N, Graham D, Blennow K, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Teunissen CE, Rabinovici GD, Rojas JC, Dage JL, Boxer AL; Advancing Research and Treatment for Frontotemporal Lobar Degeneration Investigators. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration:a retrospective diagnostic performance study[J]. Lancet Neurol, 2021, 20:739-752.
[52] van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, Papma JM, de Jong FJ, Verberk IMW, Teunissen C, Rizopoulos D, Heller C, Convery RS, Moore KM, Bocchetta M, Neason M, Cash DM, Borroni B, Galimberti D, Sanchez-Valle R, Laforce R Jr, Moreno F, Synofzik M, Graff C, Masellis M, Carmela Tartaglia M, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni GB, Cappa S, Pijnenburg YAL, Rohrer JD, van Swieten JC; Genetic Frontotemporal Dementia Initiative (GENFI). Serum neurofilament light chain in genetic frontotemporal dementia:a longitudinal, multicentre cohort study[J]. Lancet Neurol, 2019, 18:1103-1111.
[53] Rojas JC, Wang P, Staffaroni AM, Heller C, Cobigo Y, Wolf A, Goh SM, Ljubenkov PA, Heuer HW, Fong JC, Taylor JB, Veras E, Song L, Jeromin A, Hanlon D, Yu L, Khinikar A, Sivasankaran R, Kieloch A, Valentin MA, Karydas AM, Mitic LL, Pearlman R, Kornak J, Kramer JH, Miller BL, Kantarci K, Knopman DS, Graff-Radford N, Petrucelli L, Rademakers R, Irwin DJ, Grossman M, Ramos EM, Coppola G, Mendez MF, Bordelon Y, Dickerson BC, Ghoshal N, Huey ED, Mackenzie IR, Appleby BS, Domoto-Reilly K, Hsiung GR, Toga AW, Weintraub S, Kaufer DI, Kerwin D, Litvan I, Onyike CU, Pantelyat A, Roberson ED, Tartaglia MC, Foroud T, Chen W, Czerkowicz J, Graham DL, van Swieten JC, Borroni B, Sanchez-Valle R, Moreno F, Laforce R, Graff C, Synofzik M, Galimberti D, Rowe JB, Masellis M, Finger E, Vandenberghe R, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler CR, Gerhard A, Levin J, Danek A, Otto M, Sorbi S, Cash DM, Convery RS, Bocchetta M, Foiani M, Greaves CV, Peakman G, Russell L, Swift I, Todd E, Rohrer JD, Boeve BF, Rosen HJ, Boxer AL; ALLFTD and GENFI Consortia. Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration[J]. Neurology, 2021, 96:e2296-e2312.
[54] Davydow DS, Brasfield M, Morrow CB, Staffaroni AM, Pontone GM, Asken BM. Neurofilament light chain and differentiation of behavioral variant frontotemporal dementia from psychiatric disorders:a systematic review[J]. JAMA Psychiatry, 2026, 83:85-98.
[55] Wang Y, Liu YM. Advances in fluid biomarkers of frontotemporal dementia[J]. Shen Jing Sun Shang Yu Gong Neng Chong Jian, 2024, 19:784-787[. 王玥, 刘益萌. 额颞叶痴呆体液标志物研究进展[J]. 神经损伤与功能重建, 2024, 19:784-787. ]
[56] Cousins KAQ, Phillips JS, Irwin DJ, Lee EB, Wolk DA, Shaw LM, Zetterberg H, Blennow K, Burke SE, Kinney NG, Gibbons GS, McMillan CT, Trojanowski JQ, Grossman M. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration[J]. Alzheimers Dement, 2021, 17:822-830.
[57] Yang Y, Cheng Q, Gao J, Kim WS. Status of biomarker development for frontotemporal dementia and amyotrophic lateral sclerosis[J]. Neural Regen Res, 2024, 19:2117-2118.
[58] Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group; Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology:a systematic review and Meta-analysis[J]. JAMA Neurol, 2019, 76:1035-1048.
[59] Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD. Advances and controversies in frontotemporal dementia:diagnosis, biomarkers, and therapeutic considerations[J]. Lancet Neurol, 2022, 21:258-272.
[60] Katzeff JS, Bright F, Phan K, Kril JJ, Ittner LM, Kassiou M, Hodges JR, Piguet O, Kiernan MC, Halliday GM, Kim WS. Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis[J]. Brain, 2022, 145:1598-1609.
[61] Foiani MS, Woollacott IO, Heller C, Bocchetta M, Heslegrave A, Dick KM, Russell LL, Marshall CR, Mead S, Schott JM, Fox NC, Warren JD, Zetterberg H, Rohrer JD. Plasma tau is increased in frontotemporal dementia[J]. J Neurol Neurosurg Psychiatry, 2018, 89:804-807.
[62] Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V, Trojanowski JQ, Levey AI. Reduced CSF p -Tau181 to Tau ratio is a biomarker for FTLD-TDP[J]. Neurology, 2013, 81:1945-1952.
[63] Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, Sorbi S, Scarpini E, Padovani A. CSF p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2015, 16(1/2):86-91.
[64] Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L, Papma JM, Panman JL, van der Ende EL, Dopper EG, Franzen S, Graff C, Boxer AL, Rosen HJ, Sanchez-Valle R, Galimberti D, Pijnenburg YAL, Benussi L, Ghidoni R, Borroni B, Laforce R Jr, Del Campo M, Teunissen CE, van Minkelen R, Rojas JC, Coppola G, Geschwind DH, Rademakers R, Karydas AM, Öijerstedt L, Scarpini E, Binetti G, Padovani A, Cash DM, Dick KM, Bocchetta M, Miller BL, Rohrer JD, Petrucelli L, van Swieten JC, Lee SE. Poly (GP), neurofilament and grey matter deficits in C9 orf72 expansion carriers[J]. Ann Clin Transl Neurol, 2018, 5:583-597.
[65] Lehmer C, Oeckl P, Weishaupt JH, Volk AE, Diehl-Schmid J, Schroeter ML, Lauer M, Kornhuber J, Levin J, Fassbender K, Landwehrmeyer B; German Consortium for Frontotemporal Lobar Degeneration; Schludi MH, Arzberger T, Kremmer E, Flatley A, Feederle R, Steinacker P, Weydt P, Ludolph AC, Edbauer D, Otto M. Poly-GP in cerebrospinal fluid links C9 orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD[J]. EMBO Mol Med, 2017, 9:859-868.
[66] Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration[J]. Neurology, 2008, 71:1235-1239.
[67] Meeter LH, Patzke H, Loewen G, Dopper EG, Pijnenburg YA, van Minkelen R, van Swieten JC. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers[J]. Dement Geriatr Cogn Dis Extra, 2016, 6:330-340.
[68] Tarutani A, Adachi T, Akatsu H, Hashizume Y, Hasegawa K, Saito Y, Robinson AC, Mann DMA, Yoshida M, Murayama S, Hasegawa M. Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43[J]. Acta Neuropathol, 2022, 143:613-640.
[69] Wang J, Dai L, Zhang Z. Protein aggregation in neurodegenerative diseases[J]. Chin Med J (Engl), 2025, 138:2753-2768.

Please choose a citation manager

Content to export